These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 8009586

  • 1. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA.
    Transplantation; 1994 Jun 15; 57(11):1537-43. PubMed ID: 8009586
    [Abstract] [Full Text] [Related]

  • 2. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, Bluestone JA.
    J Immunol; 1995 Aug 01; 155(3):1544-55. PubMed ID: 7636216
    [Abstract] [Full Text] [Related]

  • 3. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA.
    J Immunol; 1992 Jun 01; 148(11):3461-8. PubMed ID: 1534096
    [Abstract] [Full Text] [Related]

  • 4. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M, Brown SA, Tutt LM, Tan J, Seehafer DL, Harris JP, Xun CQ, Thompson JS.
    Clin Transplant; 1997 Oct 01; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [Abstract] [Full Text] [Related]

  • 5. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS, Anasetti C, Tso JY.
    J Immunol; 1997 Oct 01; 159(7):3613-21. PubMed ID: 9317161
    [Abstract] [Full Text] [Related]

  • 6. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun 01; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 7. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF.
    Eur J Immunol; 1995 Jun 01; 25(6):1492-6. PubMed ID: 7614975
    [Abstract] [Full Text] [Related]

  • 8. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM.
    J Immunol Methods; 2004 Feb 01; 285(1):111-27. PubMed ID: 14871540
    [Abstract] [Full Text] [Related]

  • 9. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
    Li B, Wang H, Dai J, Ji J, Qian W, Zhang D, Hou S, Guo Y.
    Immunology; 2005 Dec 01; 116(4):487-98. PubMed ID: 16313362
    [Abstract] [Full Text] [Related]

  • 10. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts.
    Alegre ML, Peterson LJ, Jeyarajah DR, Weiser M, Bluestone JA, Thistlethwaite JR.
    J Immunol; 1994 Sep 15; 153(6):2738-49. PubMed ID: 8077678
    [Abstract] [Full Text] [Related]

  • 11. In vitro characterization of five humanized OKT3 effector function variant antibodies.
    Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PW, Bluestone JA, Jolliffe LK, Zivin RA.
    Cell Immunol; 2000 Feb 25; 200(1):16-26. PubMed ID: 10716879
    [Abstract] [Full Text] [Related]

  • 12. Humanization of the murine anti-human CD3 monoclonal antibody OKT3.
    Adair JR, Athwal DS, Bodmer MW, Bright SM, Collins AM, Pulito VL, Rao PE, Reedman R, Rothermel AL, Xu D.
    Hum Antibodies Hybridomas; 1994 Feb 25; 5(1-2):41-7. PubMed ID: 7858182
    [Abstract] [Full Text] [Related]

  • 13. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
    Silva HM, Vieira PM, Costa PL, Pimentel BM, Moro AM, Kalil J, Maranhão AQ, Coelho V, Brigido MM.
    Immunol Lett; 2009 Aug 15; 125(2):129-36. PubMed ID: 19573559
    [Abstract] [Full Text] [Related]

  • 14. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
    Brown SA, Lucas BA, Waid TH, McKeown JW, Barve S, Jackson LR, Thompson JS.
    Clin Transplant; 1996 Dec 15; 10(6 Pt 2):607-13. PubMed ID: 8996751
    [Abstract] [Full Text] [Related]

  • 15. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H.
    Eur J Immunol; 1993 Feb 15; 23(2):403-11. PubMed ID: 8436176
    [Abstract] [Full Text] [Related]

  • 16. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
    Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA.
    J Immunol; 1992 May 01; 148(9):2756-63. PubMed ID: 1533410
    [Abstract] [Full Text] [Related]

  • 17. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
    Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C, Vasquez M, Tso JY.
    Transplantation; 1999 Aug 27; 68(4):563-71. PubMed ID: 10480417
    [Abstract] [Full Text] [Related]

  • 18. Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.
    Lv M, Li Y, Yu M, Sun Y, Lin Z, Qiao C, Luo Q, Gu X, Huang Y, Feng J, Shen B.
    Int J Biochem Cell Biol; 2007 Aug 27; 39(6):1142-55. PubMed ID: 17446118
    [Abstract] [Full Text] [Related]

  • 19. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
    Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA.
    Cancer Res; 1999 May 01; 59(9):2096-101. PubMed ID: 10232594
    [Abstract] [Full Text] [Related]

  • 20. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.